Hjalmar Flygt
Forskningsläkare vid Institutionen för medicinska vetenskaper; Hematologi
- Telefon:
- 018-611 35 06
- E-post:
- hjalmar.flygt@medsci.uu.se
- Besöksadress:
- Akademiska sjukhuset, ing 101, plan 4
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ing 100, plan 2
751 85 Uppsala
Publikationer
Senaste publikationer
-
Ingår i Leukemia, s. 781-787, 2024
- DOI för Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
- Ladda ner fulltext (pdf) av Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
-
Clinical and Genetic studies in Chronic Myeloid Leukaemia
2024
-
Ingår i Leukemia, s. 1156-1159, 2023
- DOI för The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
- Ladda ner fulltext (pdf) av The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
-
Ingår i American Journal of Hematology, s. 421-430, 2022
- DOI för Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
- Ladda ner fulltext (pdf) av Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
-
Ingår i British Journal of Haematology, s. 915-921, 2021
- DOI för Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
- Ladda ner fulltext (pdf) av Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
Alla publikationer
Artiklar i tidskrift
-
Ingår i Leukemia, s. 781-787, 2024
- DOI för Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
- Ladda ner fulltext (pdf) av Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
-
Ingår i Leukemia, s. 1156-1159, 2023
- DOI för The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
- Ladda ner fulltext (pdf) av The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
-
Ingår i American Journal of Hematology, s. 421-430, 2022
- DOI för Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
- Ladda ner fulltext (pdf) av Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
-
Ingår i British Journal of Haematology, s. 915-921, 2021
- DOI för Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
- Ladda ner fulltext (pdf) av Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
-
Ingår i European Journal of Haematology, s. 617-623, 2021
- DOI för Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
- Ladda ner fulltext (pdf) av Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study